Abstract
In this chapter we suggest an alternative way of dealing with the problem of doping in sports. We find that today’s anti-doping policies are excessive, mostly driven by ideology and political convenience, ethically problematic, insufficiently effective, costly, and are possibly leading to more harm to society than they prevent. Anti-doping cannot achieve its declared objective (eradication of doping) since it cannot overcome the strong pressure towards winning at all cost and the limited effectiveness of surveillance. We think that the discussions on doping and anti-doping should not ignore the imperfect practical outcomes of current anti-doping policies, in elite, amateur and outside sports. Today’s anti-doping is not a solution, but an increasingly costly imperfection. We do not claim to know a way to an ultimate solution, simply because none exists, but we propose to consider a pragmatic utilitarian alternative respecting public health and ethical principles. We do this by drawing parallels between current anti-doping efforts and the ‘war on drugs’. Instead of an increasingly repressive anti-doping policy based on zero-tolerance with negative side effects, we propose to discuss another imperfection, one that might come with a reduced cost to the individual and society as compared to today’s imperfection, and that is based on regulation and harm minimisation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
As Sullivan and Hagen (2002) posit, it appears likely that we carry the results of our ancestors’ several million years long evolutionary relationship with psychotropic plant substances. Our viewing of human substance-using phenomena should therefore incorporate the evolutionary implications of a long time relationship between psychotropic substances and people. For example, selective benefits of substance use may have been that neurotransmitter-analog plant chemicals were exploited as substitutes for costly, nutritionally constrained endogenous neurotransmitters (Sullivan and Hagen 2002).
References
Aitken, C., C. Delalande, and K. Stanton. 2002. Pumping iron, risking infection? Exposure to hepatitis C, hepatitis B and HIV among anabolic-androgenic steroid injectors in Victoria, Australia. Drug and Alcohol Dependence 65(3): 303–308.
Amos, A. 2008. Anti-doping policy: Rationale or rationalisation. PhD thesis. University Library, Sydney.
Banfi, G. 2011. Limits and pitfalls of athlete’s biological passport. Clinical Chemistry and Laboratory Medicine 49(9): 1417–1421.
Buss, D.M. 2001. Human nature and culture: an evolutionary psychological perspective.Journal of Personality 69(6): 955–978.
Cakic, V. 2009. Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology.” Journal of Medical Ethics 35(10): 611–615.
Campos, D.R., M. Yonamine, and R. de Moraes Moreau. 2003. Marijuana as doping in sports. Sports Medicine (Auckland, N.Z.) 33(6): 395–399.
Carlsohn, A., M. Cassel, K. Linné, and F. Mayer. 2011. How much is too much? A case report of nutritional supplement use of a high-performance athlete. British Journal of Nutrition 105(12): 1724–1728.
Christiansen, A.V. 2011. Bodily violations testing citizens training recreationally in gyms. In Doping and anti-doping policy in sport, eds. M. McNamee and V. Moller. Andover: Routledge.
Cole, C., L. Jones, J. McVeigh, A. Kicman, Q. Syed, and M. Bellis. 2010. Adulterants in illicit drugs: A review of empirical evidence. Drug Testing and Analysis 3(2): 89–96.
Currell, K., D.R. Moore, and P. Peeling. 2012. A–Z of nutritional supplements: Dietary supplements, sports nutrition foods and ergogenic aids for health and performance–Part 28. British Journal of Sports Medicine 46: 75–76.
D’Angelo, C., and C. Tamburrini. 2010. Addict to win? A different approach to doping. Journal of Medical Ethics 36(11): 700–707.
de Mondenard, J.-P. 2000. Historique et Évolution du Dopage. Annales De Toxicologie Analytique 12(1): 5–18.
de Mondenard, J.-P. 2011. Tour De France, 33 Vainqueurs Face Au Dopage, Entre 1947 Et 2010 – Historique de L’évolution du Dopage dans le Cyclisme. Paris: Hugo et Compagnie.
Degenhardt, L., and W. Hall. 2012. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 379(9810): 55–70.
Degenhardt, L., W.T. Chiu, N. Sampson, and R.C. Kessler. 2008. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: Findings from the WHO world mental health surveys. PLoS Medicine 5(7): 1053–1067.
Donohue, J.J., B. Ewing, and D. Peloquin. 2011. Rethinking America’s illegal drug policy. Cambridge, MA: National Bureau of Economic Research.
EMCDDA. 2010. Harm reduction: Evidence, impacts and challenges. Luxembourg: Publications Office of the European Union.
Fincoeur, B. 2009. Lutte Antidopage et Cyclisme à Deux Vitesses: Évolution du Rapport au Dopage chez les Cyclistes Belges depuis l’Affaire Festina. Revue Internationale De Criminologie Et De Police Technique Et Scientifique 3(9): 207–220.
Frederick, D.A., J. Lever, and L.A. Peplau. 2007. Interest in cosmetic surgery and image: Views of men and women the lifespan. Plastic and Reconstructive Surgery 120(5): 1407–1415.
Garland, D. 2008. On the concept of moral panic. Crime, Media, Culture 4(1): 9–30.
GCDP. 2011. Report of the global commission on drug policy. www.Globalcommissionondrugs.org.
Jelsma, M. 2003. Drugs in the UN system: The unwritten history of the 1998 United Nations General Assembly special session on drugs. The International Journal on Drug Policy 14(2): 181–195.
Jones, L., L. Pickering, H. Sumnall, J. McVeigh, and M.A. Bellis. 2010. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review. The International Journal on Drug Policy 21(5): 335–342.
Kanayama, G., J.I. Hudson, and H.G. Pope. 2010. Illicit anabolic-androgenic steroid use. Hormones and Behavior 58(1): 111–121.
Kayser, B., and A. Smith. 2008. Globalisation of anti-doping: The reverse side of the medal. British Medical Journal (Clinical Research Edition) 337: a584.
Kayser, B., A. Mauron, and A. Miah. 2005. Viewpoint: Legalisation of performance-enhancing drugs. Lancet 366(Suppl 1): S21.
Kayser, B., A. Mauron, and A. Miah. 2007. Current anti-doping policy: A critical appraisal. BMC Medical Ethics 8: 2.
Kohler, M., A. Thomas, H. Geyer, M. Petrou, W. Schänzer, and M. Thevis. 2010. Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne doping control laboratory 2009. Drug Testing and Analysis 2(11–12): 533–537.
Kraska, P.B., C.R. Bussard, and J.J. Brent. 2010. Trafficking in bodily perfection: Examining the late-modern steroid marketplace and its criminalization. Justice Quarterly 27(2): 159–185.
Larance, B., L. Degenhardt, J. Copeland, and P. Dillon. 2008. Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs. Drug and Alcohol Review 27(6): 679–686.
Lentillon-Kaestner, V., and F. Ohl. 2011. Can we measure accurately the prevalence of doping? Scandinavian Journal of Medicine & Science in Sports 21(6): e132–e142.
Lentillon-Kaestner, V., M. S. Hagger, and S. Hardcastle. 2011. Health and doping in elite-level cycling. Scandinavian Journal of Medicine & Science in Sports. Health and Doping in Elite-Level Cycling (March 10): e-pub ahead of print.
Lippi, G., and M. Plebani. 2011. Athlete’s biological passport: To test or not to test? Clinical Chemistry and Laboratory Medicine: CCLM/FESCC 49(9): 1393–1395.
Loland, S., and H. Hoppeler. 2011. Justifying anti-doping: The fair opportunity principle and the biology of performance enhancement. European Journal of Sport Science 12: 347–353.
McDowall, J.A. 2007. Supplement use by young athletes. Journal of Sports Science and Medicine 6(3): 337–342.
McNamee, M.J., and L. Tarasti. 2010. Juridical and ethical peculiarities in doping policy. Journal of Medical Ethics 36(3): 165–169.
McVeigh, J., and C. Beynon. 2003. New challenges for agency based syringe exchange schemes: Analysis of 11 years of data (1991–2001) in Merseyside and Cheshire, United Kingdom. The International Journal on Drug Policy 14(5–6): 399–405.
Melnik, B.C. 2009. Androgen abuse in the community. Current Opinion in Endocrinology, Diabetes, and Obesity 16(3): 218–223.
Mendoza, J. 2002. The war on drugs in sport: A perspective from the front-line. Clinical Journal of Sport Medicine 12(4): 254–258.
Nature. 2007. A sporting chance. 448(7153): 512.
Parkinson, A.B., and N.A. Evans. 2006. Anabolic androgenic steroids: A survey of 500 users. Medicine and Science in Sports and Exercise 38(4): 644–651.
Perneger, T. 2010. Speed trends of major cycling races: Does slower mean cleaner? International Journal of Sports Medicine 31(04): 261–264.
Petróczi, A. 2007. Attitudes and doping: A structural equation analysis of the relationship between Athletes’ attitudes, sport orientation and doping behaviour. Substance Abuse Treatment, Prevention, and Policy 2: 34.
Petróczi, A., and T. Nepusz. 2011. Methodological considerations regarding response bias effect in substance use research: Is correlation between the measured variables sufficient? Substance Abuse Treatment, Prevention, and Policy 6(1): 1.
Petróczi, A., G. Taylor, and D.P. Naughton. 2011a. Mission impossible? Regulatory and enforcement issues to ensure safety of dietary supplements. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 49(2): 393–402.
Petróczi, A., J. Mazanov, and D.P. Naughton. 2011b. Inside athletes’ minds: Preliminary results from a pilot study on mental representation of doping and potential implications for anti-doping. Substance Abuse Treatment, Prevention, and Policy 6: 10.
Pitsch, W. 2009. ‘The science of doping’ revisited: Fallacies of the current anti-doping regime. European Journal of Sport Science 9(2): 87–95.
Pitsch, W., and E. Emrich. 2011. The frequency of doping in elite sport: Results of a replication study. International Review for the Sociology of Sport (August 23). E-pub before print.
Room, R., and P. Reuter. 2012. How well do international drug conventions protect public health? Lancet 379(9810): 84–91.
Sanchis-Gomar, F., V.E. Martinez-Bello, M.-C. Gomez-Cabrera, and J. Viña. 2011. Current limitations of the athlete’s biological passport use in sports. Clinical Chemistry and Laboratory Medicine 49(9): 1413–1415.
Saugy, M., L. Avois, C. Saudan, N. Robinson, C. Giroud, P. Mangin, and J. Dvorak. 2006. Cannabis and sport. British Journal of Sports Medicine 40(Suppl 1): i13–i15.
Schweizerische Eidgenössische Kommission für Drogenfragen (SEKD). 2006. Von Der Politik Der Illegalen Drogen Zur Politik Der Psychoaktiven Substanzen. Bern: Huber.
Smith, M.E., and M.J. Farah. 2011. Are prescription stimulants ‘smart pills’? the epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychological Bulletin 137(5): 717–741.
Sottas, P.E., N. Robinson, G. Fischetto, G. Dolle, J.M. Alonso, and M. Saugy. 2011. Prevalence of blood doping in samples collected from elite track and field athletes. Clinical Chemistry 57(5): 762–769.
Striegel, H., P. Simon, S. Frisch, K. Roecker, K. Dietz, H.-H. Dickhuth, and R. Ulrich. 2006. Anabolic ergogenic substance users in fitness-sports: A distinct group supported by the health care system. Drug and Alcohol Dependence 81(1): 11–19.
Striegel, H., R. Ulrich, and P. Simon. 2010. Randomized response estimates for doping and illicit drug use in elite athletes. Drug and Alcohol Dependence 106(2–3): 230–232.
Sullivan, R.J., and E.H. Hagen. 2002. Psychotropic substance-seeking: Evolutionary pathology or adaptation? Addiction 97(4): 389–400.
Teter, C.J., S.E. McCabe, K. LaGrange, J.A. Cranford, and C.J. Boyd. 2006. Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacotherapy 26(10): 1501–1510.
WADA. 2009. World anti-doping code. www.wada-ama.org.
WADA. 2012. International standard of testing. www.wada-ama.org.
Wiesing, U. 2011. Should performance-enhancing drugs in sport be legalized under medical supervision? Sports Medicine (Auckland, N.Z.) 41(2): 167–176.
Wood, E., D. Werb, B. Marshall, J. Montaner, and T. Kerr. 2009. The war on drugs: A devastating public-policy disaster. Lancet 373(9668): 989–990.
Yesalis, C.E., and M.S. Bahrke. 2002. History of doping in sport. In Performance-enhancing substances in sport and exercise, ed. Charles E. Yesalis and Michael S. Bahrke. Champaign: Human Kinetics.
Zorzoli, M. 2011. The athlete biological passport from the perspective of an anti-doping organization. Clinical Chemistry and Laboratory Medicine 49(9): 1423–1425.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Kayser, B., Broers, B. (2013). Anti-doping Policies: Choosing Between Imperfections. In: Tolleneer, J., Sterckx, S., Bonte, P. (eds) Athletic Enhancement, Human Nature and Ethics. International Library of Ethics, Law, and the New Medicine, vol 52. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5101-9_15
Download citation
DOI: https://doi.org/10.1007/978-94-007-5101-9_15
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-5100-2
Online ISBN: 978-94-007-5101-9
eBook Packages: Humanities, Social Sciences and LawPhilosophy and Religion (R0)